newsfilter
← Latest News
ACCESS Newswire·

Lexaria Provides Progress Report on Six R&D Programs

All studies are using DehydraTECH™ 2.0 formulations for multiple market applications, including antivirals, hypertension, NSAIDs and oral nicotine These studies are part of Lexaria's 2021 applied R&D program intended to enable opportunities for strat